Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Broad Institute
Backed with $500m to look into the mechanistic underpinnings of unmet medical needs, Arena BioWorks will employ a hub-and-spoke model to incubate biotechs around a central technology hub.
The recent ASH meeting began with US FDA approvals of the first genetic medicines for sickle cell disease, but doctors and biopharma companies still see a need for new oral therapies and other options.
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
Kate is focused on delivering gene therapies for two rare, neuromuscular diseases by deploying AAV technology that it says will target muscle tissue and enable regulated therapeutic payloads.
- Academic and Research Institutions
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.